LIQUIDIA CORP (LQDA) Stock News
NASDAQ:LQDA - Nasdaq - US53635D2027 - Common Stock - Currency: USD
LQDA Latest News, Press Relases and Analysis
Liquidia Receives $50 Million from Healthcare Royalty (HCRx) Following First Commercial Sale of YUTREPIA™
Liquidia Receives $50 Million from Healthcare Royalty (HCRx) Following First Commercial Sale of YUTREPIA™
MORRISVILLE, N.C., June 23, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for...
Insmed Catapults Into Breakout Territory On A 'Home Run' For Its Rival To United, Liquidia
Shares look likely to break out at the open after the biotech company unveiled promising results for a pulmonary arterial hypertension treatment.
Liquidia Schedules First Commercial Shipment of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD
YUTREPIA now available to be prescribed to patients via specialty pharmaciesFDA approved YUTREPIA on May 23, 2025Court denies United Therapeutics’ request...
Liquidia Schedules First Commercial Shipment of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD
Liquidia Corporation to Present at the 2025 Jefferies Global Healthcare Conference
MORRISVILLE, N.C., May 28, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that the company’s Chief Executive Officer Dr....
Liquidia Corporation to Present at the 2025 Jefferies Global Healthcare Conference
U.S. FDA Approves Liquidia’s YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
FDA’s approval of YUTREPIA paves the way for prescribers to add a new treatment option for patients with PAH and PH-ILDYUTREPIA is designed to enhance...
Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics
New litigation filed against Liquidia in U.S. District Court for the Middle District of North Carolina alleges infringement of UTHR’s ‘782 patent and seeks...
Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics
Buckley Capital’s Views on Liquidia Corp. (LQDA)
Buckley Capital Advisors, an investment management company, released its first quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund returned -0.5% (net) in the quarter compared to -7.7% return for iShares Russell 2000 Value Index and -9.5% return for the iShares Russell 2000 Index. In the quarter, Donald Trump’s […]
Liquidia Technologies, Inc. (LQDA) Reports Q1 Loss, Misses Revenue Estimates
Liquidia Technologies (LQDA) delivered earnings and revenue surprises of -7.14% and 5.66%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: ROIV
Liquidia Corporation Reports First Quarter 2025 Financial Results and Provides Corporate Update
Awaiting FDA action on YUTREPIA™ NDA with a PDUFA goal date of May 24, 2025District Court dismissed cross claim filed by United Therapeutics challenging...
Liquidia Corporation Reports First Quarter 2025 Financial Results and Provides Corporate Update
Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates
Merus (MRUS) delivered earnings and revenue surprises of -20.69% and 238.55%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: MRUS